Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotech advancing novel therapies for fibro-inflammatory diseases. This news hub provides investors and researchers with essential updates on nebokitug (CM-101), the company's lead monoclonal antibody targeting CCL24 in conditions like primary sclerosing cholangitis (PSC) and systemic sclerosis.
Access timely reports on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes verified updates from Phase 2/3 trials, FDA/EMA designations, and scientific conference presentations. Key focus areas span biomarker validation, trial enrollment status, and intellectual property developments.
This resource serves as your central source for tracking Chemomab's progress in addressing high-need rare diseases. Bookmark this page for direct access to primary documents including SEC filings, peer-reviewed data publications, and official press releases. Check regularly for updates on the upcoming Phase 3 PSC trial and expansion into new fibrotic disease indications.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a biotechnology firm specializing in innovative therapeutics for fibro-inflammatory diseases, announced its participation in the Aegis 2023 Virtual Investor Conference from May 2 to May 4, 2023. Chemomab's management will present a corporate overview on May 3, 2023, at 9:00 AM EDT. The event will be held virtually, and investors can access the webcast through a provided link.
Additionally, Chemomab's corporate development team will attend the BIO International Convention's One-on-One Partnering™ event in Boston from June 5 to June 8, 2023. They encourage registered attendees to schedule meetings via an online portal.
The company focuses on creating therapies like CM-101, a monoclonal antibody aimed at treating severe fibro-inflammatory diseases, backed by ongoing Phase 2 trials.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced its participation in several scientific conferences during April and May 2023. Key events include the British Society for Rheumatology Annual Conference from April 24-26, where Chemomab will present an oral presentation on CCL24 serum concentration and its relevance in systemic sclerosis. The second event is the EASL Monothematic Conference on Biliary Fibrosis from May 12-13, highlighting a poster presentation on the role of CCL24 in cholestatic disease. Additionally, Chemomab's corporate development team will attend the BIO International Convention in Boston from June 5-8, focusing on partnership opportunities. Chemomab aims to advance innovative therapeutics for fibro-inflammatory diseases, particularly through its monoclonal antibody CM-101, which targets CCL24.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, will hold a webcast and conference call on May 11, 2023, at 8:00 am ET to discuss its first quarter 2023 financial results and provide a corporate update. This event replaces a previous update originally set for April 17, 2023. During the call, the management team will review the company's performance, recent developments, and host a Q&A session. A replay will be available on their website for 90 days. Chemomab focuses on developing therapeutics for fibro-inflammatory diseases and has seen promising results from its lead product, CM-101, in various ongoing studies.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) will hold a Corporate Update on April 17, 2023, at 8:00 am Eastern Time. This replaces a previously scheduled webcast on March 31, 2023. The management team will review recent developments and answer questions from investors. Chemomab focuses on innovative therapies for fibro-inflammatory diseases, with CM-101 showing promise in trials for liver fibrosis and severe lung injury in COVID-19 patients. A Phase 2 trial for primary sclerosing cholangitis is ongoing, and a similar trial for systemic sclerosis is expected to open mid-2023.
Chemomab Therapeutics (Nasdaq: CMMB) will present its Q4 and full-year 2022 financial results on March 31, 2023, at 8:00 am Eastern Time. The management team will review the company’s performance and discuss future developments during the call, which includes a live question-and-answer session. Notably, the company focuses on developing therapeutics to address fibro-inflammatory diseases. Their key product, CM-101, aims to treat severe diseases related to fibrosis and inflammation, with recent positive results from clinical studies. A replay of the event will be available for 90 days on their website.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
